Brainstorm Cell Therapeutics (BCLI) Financials

$1.05

$-0.02 (-1.87%)

As on 04-Sep-2026 12:51EDT

Market cap

$12 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

54.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	0.88	0.70	0.85	--	--	--
Cost of Revenue	0.13	--	0.24	0.27	0.29	0.26
Gross Profit	-0.13	--	-0.24	-0.27	-0.29	-0.26
Operating Expenses	9.82	9.95	11.69	21.17	24.82	24.54
Operating Profit (EBIT)	-9.95	-9.95	-11.69	-21.44	-24.82	-24.54
Other Income	--	--	--	--	--	--
Profit before Tax	-10.52	-10.31	11.62	-17.19	-24.28	-24.46
Provision for Tax	--	--	11.62	--	-0.55	-0.08
Profit after Tax (Net Income)	-10.52	-10.31	11.62	-17.19	-23.73	-24.46
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-24.28	-24.46

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-11.60	-10.29	-7.76	-4.86	-3.02	19.34
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	0.21	0.62	1.27	2.67	3.62
Current Liabilities	12.39	11.01	8.98	7.80	8.80	6.32
Total Liabilities	12.86	0.72	1.83	4.21	8.45	29.28

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.16	0.41	1.45	2.31	5.35	6.00
Current Assets	0.32	0.31	0.39	1.90	3.11	23.28
Total Assets	0.79	0.72	1.83	4.21	8.45	29.28
Total Debt*	1.37	0.21	0.72	1.28	4.09	5.08
Net Current Assets	--	-10.70	-8.59	-5.90	-5.69	16.96

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-6.98	-9.09	-20.46	-19.32	-26.27
Cash Flow from Investing Activities	--	--	0.01	2.19	1.00	0.32
Cash from Financing Activities	--	6.88	7.97	18.98	0.24	6.97
Net Cash Inflow / Outflow	--	--	--	--	--	-18.97

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-1.00	-1.11	2.04	-5.83	-9.72	-10.10
Cash EPS ($)	--	-1.09	2.08	-5.74	-9.60	-10.00
Adjusted Book Value ($)	--	--	--	--	--	7.99
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.75	-1.59	-6.93	-7.91	-10.85
Free Cash Flow per Share ($)	--	-0.75	-1.59	-6.94	-7.93	-10.99

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	120.35	-218.74	1,372.61	-186.14	-72.89
ROE (%)	--	114.17	-184.17	436.73	-290.71	-89.25
ROA (%)	-177.11	-809.34	384.87	-271.62	-125.81	-60.74
EBIT Margin (%)	-1,129.40	-1,415.79	-1,359.95	--	--	--
Net Margin (%)	-1,194.32	-1,466.15	1,369.02	--	--	--
Cash Profit Margin (%)	-0.01	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	3.77	-0.17	--	--	--	--
EBIT Growth (%)	16.38	13.80	32.84	30.74	-1.15	22.55
Net Profit Growth (%)	8.09	-188.68	167.61	27.56	2.96	23.12
EPS Growth (%)	45.28	-1.55	1.35	0.40	0.04	0.32
Book Value Growth (%)	-49.57	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.50	1.11	-0.05	-0.17	-0.40
Price / Book Value	54.50	-0.50	-1.67	-0.17	-1.33	0.50
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.70	-0.54	-1.19	-0.05	-0.21	0.30
Close Price ($)	0.90	0.55	2.27	4.10	24.60	60.00
High Price ($)	1.32	2.37	11.89	51.90	70.50	122.10
Low Price ($)	0.46	0.52	1.05	2.01	16.28	41.25
Market Cap ($ Cr)	12.36	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	-0.02	-0.09	-0.26	-1.36	0.26
Short term debt to equity ratio	-0.12	-0.02	-0.07	-0.12	-0.47	0.08
Current Ratio	0.03	0.03	0.04	0.24	0.35	3.69
Quick Ratio	0.03	--	--	0.25	--	--
Interest Coverage	1,504.14	--	-149.95	--	-45.54	-299.26

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	18.39	12.23	7.42	--	--	--
Asset Turnover	0.15	0.55	0.28	--	--	--
Receivable days	--	38.71	24.52	--	--	--
Inventory Days	--	--	-77.62	-70.29	--	--
Payable days	--	--	8,396.18	7,703.33	6,359.19	6,403.82
Cash Conversion Cycle	--	--	-8,449.28	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.